Clinical trial Recruiting at 10 sites Interventional Ages 18 and up

Comparing low and standard dose-intensity continuous renal replacement therapy in critically ill patients

Official title: LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM): A Pilot Randomized Trial

Run by University of Alberta · NCT06446739 · Data updated 2026-11-12

This study is testing if a lower dose of kidney treatment is just as good as the standard dose for critically ill patients with acute kidney injury.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversity of Alberta
Academic / other
Locations10 sites (Rochester, Minnesota and 9 other locations)
StatusRecruiting
StartedNovember 14, 2024
Main results expectedDecember 2026
Study endsJune 2027
Registry record updatedOctober 28, 2026
Trial IDNCT06446739 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are critically ill adults aged 18 years and older who are expected to receive continuous renal replacement therapy for acute kidney injury.

Probably not a fit

Patients with end-stage kidney disease requiring maintenance dialysis or those needing higher dose-intensity CRRT will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The WISDOM trial aims to evaluate whether a lower dose-intensity of continuous renal replacement therapy (CRRT) is as effective as the standard dose-intensity for critically ill patients suffering from acute kidney injury (AKI). This interventional study will compare the outcomes of patients receiving lower dose-intensity CRRT against those receiving the standard guideline-directed dose. The primary goal is to determine if the lower dose is non-inferior in terms of CRRT duration and kidney recovery. Additionally, the study will assess if the lower dose can lead to shorter CRRT duration and improved recovery outcomes. This trial is significant as it addresses a gap in current clinical guidelines regarding the minimum effective dose of CRRT.

Why it matters

Potential benefit: If successful, this study could lead to more cost-effective and less invasive treatment options for critically ill patients with acute kidney injury.

How similar studies have gone: While previous studies have explored CRRT dose-intensity, this trial is novel as it specifically investigates the lower dose-intensity threshold, which has not been previously evaluated in randomized controlled trials.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age ≥ 18 years
* weight ≥ 55 kg
* plan to initiate CRRT or within 24 hours of having started CRRT for AKI
* expected to survive and receive CRRT for a duration of ≥ 48 hours
* able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).

Exclusion Criteria:

* indication for sustained higher dose-intensity CRRT as designated by the attending clinicians
* end-stage kidney disease receiving maintenance dialysis
* receipt of any RRT for AKI during the current hospitalization
* inability to comply with the requirements of the study protocol.

Where it's running

  • Mayo Clinic
    Rochester, Minnesota, United States
    Recruiting
  • Foothills Medical Centre
    Calgary, Alberta, Canada
    Recruiting
  • University of Alberta Hospital
    Edmonton, Alberta, Canada
    Recruiting
  • Grey Nuns Hospital
    Edmonton, Alberta, Canada
    Recruiting
  • Sturgeon Community Hospital
    St. Albert, Alberta, Canada
    Recruiting
  • Hamilton General Hospital
    Hamilton, Ontario, Canada
    Recruiting
Show 4 more locations
  • Sunnybrook Health Sciences Centre
    North York, Ontario, Canada
    Recruiting
  • St Michael's Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Regina General Hospital/Saskatchewan Health Authority
    Regina, Saskatchewan, Canada
    Recruiting
  • Guy's & St Thomas' Hospitals
    London, United Kingdom
    Recruiting

Study contacts

  • Principal investigator: Sean M Bagshaw, MD — University of Alberta
  • Study coordinator: Sean M Bagshaw, MD
  • Email: bagshaw@ualberta.ca
  • Phone: 780-248-1256

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.